A Phase 1 interventional study of ALXN1007 and Placebo in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-03.
Sponsored by Alexion Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.
All subjects will be screened for eligibility after providing signed informed consent. Once a subject is determined to be eligible, the subject will be vaccinated with the quadrivalent meningococcal conjugate vaccine at least two weeks prior to dosing, if applicable. A total of 7 dose cohorts will be enrolled sequentially and randomized to receive ALXN1007 or placebo. Subjects will receive ALXN1007 or placebo at the clinic and be kept at the clinic for a total of 4 days for observation and completion of the required study tests.
The subjects will return for 8 additional clinic visits to complete the required study tests over the next 86 days. The total duration of the study is 90 days from the day of dosing with ALXN1007 or placebo.
Alexion Pharmaceuticals, Inc. is the lead sponsor of 249 studies on the registry; 25 are open to participants now.
Of its 98 completed or terminated interventional studies of FDA-regulated products, 70 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
0.06 mg/kg ALXN1007
Drug: ALXN1007 · Other: Placebo
0.1 mg/kg ALXN1007
Drug: ALXN1007 · Other: Placebo
0.3 mg/kg ALXN1007
Drug: ALXN1007 · Other: Placebo
1.0 mg/kg ALXN1007
Drug: ALXN1007 · Other: Placebo
3.0 mg/kg ALXN1007
Drug: ALXN1007 · Other: Placebo
6.0 mg/kg ALXN1007
Drug: ALXN1007 · Other: Placebo
10.0 mg/kg ALXN1007
Drug: ALXN1007 · Other: Placebo
Single dose, IV
Single dose, IV
Safety and tolerability of a single dose of ALXN1007.
Safety and tolerability of a single dose of ALXN1007 assessed by physical exam, vital signs, ECG, immunogenicity, lab analysis and adverse events.
Time frame: Up to 90 days
PK parameters of ALXN1007
Estimate PK parameters of ALXN1007 using standard measures for these parameters.
Time frame: Up to 90 days
PD parameters of ALXN1007
Identify PD effects of ALXN1007 by assessing standard complement measures for these parameters.
Time frame: Up to 90 days
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alexion Pharmaceuticals, Inc.